ANTICIPATING TREATMENT NON-PERSISTENCE THROUGH AN INNOVATIVE CONCEPTUAL FRAMEWORK

Published Mar 7, 2015
Paderborn, Germany - Using principles from behavioral economics to model patient decisions, innovative research published in Value in Health proposes a framework to understand the reasons for treatment non-persistence and predicts the point at which a patient will stop taking their medication. This information could contribute to the development of tailored intervention solutions to ensure the patient stays on track and continues taking their medicine as prescribed. The conceptual model described in the article, “Conceptual Model and Economic Experiments to Explain Non-persistence and Enable Mechanism Designs Fostering Behavioral Change,” bridges the economic principles of loss aversion and mental accounting with health behavior. The model highlights that a point exists where a patient feels that they have been adequately compensated for their perceived losses, such as effort to travel to see their doctor, or loss of day at work because of ill health. It is at this point that they will stop taking their medicine and thus the benefit of persistence is no longer greater than non-persistence. “This research will equip health care professionals with a way to generate insights on patient persistence behaviors. The incorporation of this intelligence into existing strategies could lead to more sophisticated, personalized tools that work towards maintaining treatment compliance.” said co-author Prof. Dr. René Fahr, PhD, from the University of Paderborn in Paderborn, Germany. Whereas previous research has limitations in its focus solely on rational choice behavior or retrospective identification of correlations between behaviors and discontinuation, this conceptual model is prospective, scalable and can be calibrated. In practice, it may therefore result in better health outcomes for patients and a reduction in costs through more efficient health care delivery.

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

From Promise to Proof: Strengthening the Evidence Base for Digital Health Technologies

Apr 28, 2026

Value in Health announced the publication of a special themed section of research papers that advances evidence and methods for evaluating the real-world value of digital health technologies.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×